Squarepoint Ops LLC Atreca, Inc. Transaction History

Squarepoint Ops LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.61 - $5.2 $28,125 - $90,838	-17,469 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.87 - $6.29 $13,308 - $29,166	4,637 Added 36.14%	17,469 $53,000
Q3 2021 Nov 15, 2021	SELL	$4.91 - $9.07 $247,228 - $456,692	-50,352 Reduced 79.69%	12,832 $80,000
Q2 2021 Aug 16, 2021	BUY	$7.82 - $13.8 $262,705 - $463,597	33,594 Added 113.53%	63,184 $538,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $99,320 - $147,757	7,640 Added 34.81%	29,590 $454,000
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $286,008 - $375,125	21,950 New	21,950 $354,000
Q3 2020 Nov 16, 2020	SELL	$12.67 - $23.19 $263,662 - $482,583	-20,810 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$12.52 - $23.45 $260,541 - $487,994	20,810 New	20,810 $443,000
Q1 2020 May 15, 2020	SELL	$11.4 - $27.28 $418,311 - $1 Million	-36,694 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$9.68 - $18.67 $170,145 - $328,162	17,577 Added 91.94%	36,694 $568,000
Q3 2019 Nov 14, 2019	BUY	$10.42 - $22.04 $199,199 - $421,338	19,117 New	19,117 $234,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

Stay updated on Squarepoint Ops LLC with notifications on news.